Business Wire

Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (Blade or the Company), a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and ...
Business Wire

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and ...
Nature

Molecular Docking Studies and Enzyme Inhibition

Molecular docking studies represent a cornerstone in modern drug discovery by providing detailed insights into the specific interactions between bioactive compounds and target enzymes. This ...
GEN

Lymphoma Immunotherapy Enhanced by Enzyme Inhibitor In Preclinical Model, Prompting Pilot Clinical Studies

The results of a preclinical study by lymphoma researchers at Weill Cornell Medicine suggest that an emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some ...